



Early Release Paper

Deferasirox, Deferiprone and Desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative Magnetic Resonance Imaging

by Alessia Pepe, Antonella Meloni, Marcello Capra, Paolo Cianciulli, Luciano Prossomariti, Cristina Malaventura, Maria Caterina Putti, Alma Lippi, Maria Antonietta Romeo, Maria Grazia Bisconte, Aldo Filosa, Vincenzo Caruso, Antonella Quarta, Lorella Pitrolo, Massimiliano Missere, Massimo Midiri, Giuseppe Rossi, Vincenzo Positano, Massimo Lombardi, and Aurelio Maggio

Haematologica 2010 [Epub ahead of print]

Citation: Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, and Maggio A. Deferasirox, Deferiprone and Desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative Magnetic Resonance Imaging.

Haematologica. 2010; 95:xxx

doi:10.3324/haematol.2009.019042

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haematologica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature.

Support Haematologica and Open Access Publishing by becoming a member of the European Hematology Association (EHA) and enjoying the benefits of this membership, which include free participation in the online CME program

Deferasirox, Deferiprone and Desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative Magnetic Resonance Imaging

Running Title: Cardiac iron in thalassemia with DFX, DFP and DFO

Alessia Pepe¹, Antonella Meloni¹, Marcello Capra², Paolo Cianciulli³, Luciano Prossomariti⁴, Cristina Malaventura⁵, Maria Caterina Putti⁶, Alma Lippi⁷, Maria Antonietta Romeo⁸, Maria Grazia Bisconte⁹, Aldo Filosa¹⁰, Vincenzo Caruso¹¹, Antonella Quarta¹², Lorella Pitrolo¹³, Massimiliano Missere¹⁴, Massimo Midiri¹⁵, Giuseppe Rossi¹⁶, Vincenzo Positano¹, Massimo Lombardi¹, and Aurelio Maggio¹⁷

¹MRI Laboratory, Institute of Clinical Physiology, CNR/Toscana Foundation “G. Monasterio”, Pisa, Italy; ²Ematologia-Emoglobinopatie, G. Di Cristina Hospital - ARNAS, Palermo, Italy; ³Centro Talassemie, “Sant’Eugenio” Hospital, Roma, Italy; ⁴Centro per la Cura delle Microcitemie, Cardarelli Hospital, Napoli, Italy; ⁵Department of Pediatrics, University of Ferrara, Ferrara, Italy; ⁶Department of Pediatrics, University of Padova, Padova, Italy; ⁷Centro Talassemie ed Emoglobinopatie, Meyer Hospital, Firenze, Italy; ⁸Department of Pediatrics, University of Catania, Catania, Italy; ⁹Centro di Microcitemia. U. O. Ematologia, Presidio Osp. Annunziata, Cosenza, Italy; ¹⁰UOC pediatria, DH Talassemia, Cardarelli Hospital, Napoli, Italy; ¹¹Centro Microcitemia “Garibaldi” Hospital, Catania, Italy; ¹²Ematologia “A. Perrino” Hospital, Brindisi, Italy; ¹³Pediatria II per le Emopatie Ereditarie, Villa Sofia-CTO Hospital, Palermo, Italy; ¹⁴Radiology Department, “John Paul II” Catholic University, Campobasso, Italy; ¹⁵Department of Radiology, University of Palermo, Palermo, Italy; ¹⁶Epidemiology and Biostatistics Unit, Institute of Clinical Physiology, CNR, Pisa, Italy, and ¹⁷Ematologia II con Talassemia, “V. Cervello” Hospital, Palermo, Italy

Correspondence

Alessia Pepe, MRI Laboratory, Institute of Clinical Physiology, CNR/Toscana Foundation

“G. Monasterio”, Via Moruzzi, 1 56124 Pisa, Italy. Phone: international +39.050.3152818

Fax: international +39.050.3152166. E-mail: alessia.pepe@ifc.cnr.it

Acknowledgments

We thank Dr. Cristina Salvatori (“G. Monasterio” Foundation and CNR Institute of Clinical Physiology, Pisa) for database development and management, Claudia Santarlaschi (“G. Monasterio” Foundation and CNR Institute of Clinical Physiology, Pisa) for her skilful secretarial work and Alison Frank for her assistance in editing this manuscript. We would like to thank the following colleagues from the Italian thalassemia centers involved in the MIOT network for having enrolled the patients and collected the clinical data: V. De Sanctis (St Anna Hospital, Ferrara, Italy); C. Gerardi (“Ospedali Civili Riuniti” Siacca Agrigento, Italy); A. Pietrangelo (University Hospital of Modena and Reggio Emilia, Modena, Italy); S. Grimaldi (Presidio Ospedaliero ASL 5, Crotone), G. Roccamo (Ospedale “Civile”, S. Agata di Militello (ME), A. Meo (Policlinico G. Martino, Messina), M. Rizzo (Ospedale “Sant’Elia”, Caltanissetta), D. Maddaloni (Ospedale Engles Profili, Ancona). We also thank the following colleagues from the Italian MRI centres involved in the MIOT network for having acquired and collected MRI data: L. Natale (Policlinico Gemelli, Roma), G. Valeri (Ospedali Riuniti Umberto I-Lancisi-Salesi, Ancona). We also thank all patients for their cooperation.

Funding

The MIOT project received “no-profit support” from Chiesi, Bayer-Schering and GE Healthcare. It was also supported by the Italian Foundation “Leonardo Giambrone” and was undertaken on behalf of the Italian Society for Thalassemias and Hemoglobinopathies (SITE).

ABSTRACT

Background. Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has been recently made commercially available but its long-term efficacy on cardiac iron and function has not yet been established. Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major patients by means of quantitative magnetic resonance imaging.

Design and Methods. From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in Thalassemia network, we retrospectively selected thalassemia major patients who had been receiving one chelator alone for longer than 1 year. We identified three groups of patients: 24 treated with deferasirox, 42 treated with deferiprone and 89 treated with desferrioxamine. Myocardial iron concentrations were measured by T2* multislice multiecho technique. Biventricular function parameters were quantitatively evaluated by cine images. Liver iron concentrations were measured by T2* multiecho technique.

Results. The global heart T2* value was significantly higher in the deferiprone (34 ± 11 ms) than in the deferasirox (21 ± 12 ms) and the desferrioxamine groups (27 ± 11 ms) ($P=0.0001$). We found higher left ventricular ejection fractions in the deferiprone and the desferrioxamine vs the deferasirox group ($P=0.010$). Liver Iron Concentration, measured as T2* signal, was significantly lower in the desferrioxamine vs the deferiprone and the deferasirox group ($P=0.004$).

Conclusions. The cohort of patients treated with oral deferiprone showed less myocardial iron burden and better global systolic ventricular function compared to the patients treated with oral deferasirox or subcutaneous desferrioxamine.

Key words: thalassemia, iron chelation therapy, cardiac magnetic resonance imaging.

INTRODUCTION

Heart failure mainly related to iron-induced toxicity remains the leading cause of morbidity and mortality in thalassemia major patients, although life-expectancy in this population has improved in the last years (1, 2). Therefore, chelation strategies to prevent heart disease should have the highest priority (2) .

The oral chelating agent deferiprone was proved to be more effective than subcutaneous desferrioxamine for removing heart iron, measured by T2* MRI (3-5), and in improving survival (2, 6-9). Also the novel oral once-daily iron chelator deferasirox which should be able to improve compliance is now commercially available. To date, no prospective randomized studies have been published on the cardiac efficacy of deferasirox. Some recent reports have suggested that deferasirox may be effective in increasing heart T2* signal in thalassemia major patients (10-12). However, these studies did not compare all three chelators (deferasirox, deferiprone and desferrioxamine) together. Conversely, a recently published observational study of comparison among four chelator regimens did not show a statistically significant improvement in cardiac iron load in (thalassemia major) TM patients treated with deferasirox (13), although this study suffered from a variable time period between MRI scans, and it did not take compliance into account nor the doses of the chelators.

Magnetic Resonance Imaging (MRI) by the T2* technique allows highly reproducible and non invasive quantifications of myocardial (14-16) and liver (14, 17, 18) iron burden in the clinical arena, and has been contributing to the improved survival in thalassemia patients (19). Moreover, MRI is the gold standard for quantifying biventricular function parameters (20).

Therefore, the aim of our study was to compare retrospectively in a large cohort of patients with TM the effectiveness of the three available iron chelators (deferasirox, deferiprone and desferrioxamine) on myocardial and liver iron concentrations and on bi-ventricular function measured by quantitative MRI.

DESIGN AND METHODS

Study population

The MIOT (Myocardial Iron Overload in Thalassemia) project is a network involving six Italian Cardiac Magnetic Resonance (CMR) sites and 57 Italian thalassemia centres where CMR procedure is performed using homogeneous, standard and validated procedures (21). All centres are linked by a web-based network, configured to collect and share patients data (22). From the 550 thalassemia patients enrolled in the MIOT network, we retrospectively selected the 115 thalassemia major patients (73 males, age 9-56 years, mean age 31 ± 9 years) receiving one chelator alone for longer than 1 year. All patients had been regularly transfused since early childhood, starting chelation treatment with desferrioxamine in the mid-to-late 1970s.

We identified three groups of patients: 24 patients treated with deferasirox, 42 patients treated with deferiprone and 89 patients treated with desferrioxamine. The mean administered dosages of the three chelators were: 1) deferasirox 26 ± 6.3 mg/kg body weight per day (range 18-40 mg/kg body weight per day); 2) deferiprone 72 ± 10 mg/kg body weight (range 50-86 mg/kg body weight per day), divided into three doses per day; 3) desferrioxamine 30 ± 9 mg/kg body weight/infusion via subcutaneous route on 3-7 days per week (range 24-52 mg/kg body weight).

The study complied with the Declaration of Helsinki. All patients gave written informed consent to the protocol. The institutional review board approved this study.

Magnetic Resonance Imaging

At all six sites, CMR exams were performed by a 1.5 T scanner (GE Signa/Excite HD, Milwaukee, WI, USA) using previously reported cardiac-gated techniques (4, 15, 23).

In brief, for the MIO measurements, a multislice multiecho T2* approach was used. Three parallel short-axis views (basal, medium and apical) of the left ventricle (LV) were acquired at nine increasing echo times (TE) (2.2–20.3 ms) in a single end-expiratory breath-hold. The transferability of multislice multiecho T2* within the MIOT network has been previously validated (21). For the

measurement of liver iron overload, a T2* single– breath-hold, 9-echo sequence (TEs 2.0–21 ms) of a transaxial slice was acquired (17).

T2* image analysis was performed using a custom-written, previously validated software program (HIPPO MIOT®, IFC-CNR). The software was able to map the myocardial T2* distribution into a 16-segment LV model according to the American Heart Association (AHA)/American College of Cardiology (ACC) standardized myocardial segmentation (24). The intra-observer, inter-observer and inter-study and variability of the proposed methodology were previously assessed (15). The global T2* value was obtained by averaging segmental T2* values, and the T2* value in the mid-ventricular segment was obtained by averaging segmental T2* values in the mid anterior septum and the mid inferior septum. As previously shown (23, 25), the developed procedure was able to correct for cardiac/visceral geometrical and susceptibility artefacts. T2* > 20 ms was considered as a “conservative” normal value for all 16 segments, for the mid-ventricular septum and for the entire heart (14, 23).

For the liver, the decay curve was extracted from a large region of interest of standard dimensions, chosen from a homogeneous area of liver parenchyma without blood vessels, and the value of T2* was calculated by fitting the decay curve model with a single exponential with a constant offset (16, 17). We expressed the liver iron concentration (LIC) also in mg/g dry weight. We used the conversion from T2* to LIC, by using the formula, $0.202 + 25.4/T2^*$ adapted from Wood et al. (26).

Steady-state free precession cine images were acquired during 8-second breath holds in sequential 8-mm short-axis slices from the atrio-ventricular ring to the apex to assess biventricular function parameters quantitatively in a standard way (20), using MASS® software (Medis, Leiden, The Netherlands).

Statistical analysis

All data were analysed using the SPSS version 12.0 statistical package. Summary data are presented as mean \pm standard deviation. Comparisons among groups were made by one-way ANOVA for continuous values with normal distribution and Kruskal-Wallis test for continuous values with non-normal distribution (i.e. T2* data). Multiple comparisons were made by t test or Mann-Whitney test and p values were modified according to the Bonferroni correction. For non-continuous variables, χ^2 testing was performed. Correlation analysis was performed using Spearman's test. A two-tailed probability value of 0.05 was considered statistically significant.

RESULTS

The three groups were no different for gender, pre-transfusional Hb levels, age at the first chelation, compliance to the active chelation treatment, previous intensive chelation therapies (24 hour infusions of desferrioxamine through portacaths and/or combination therapy with desferrioxamine and deferiprone). The deferasirox group was significantly younger than the deferiprone and the desferrioxamine groups ($P=0.0001$). Desferrioxamine treatment had been started significantly earlier (24 ± 10 years, range 1-47 years) than the deferiprone treatment (4 ± 4 years, range 1-18 years) ($P<0.0001$) and the deferasirox treatment (2 ± 1 years, range 1-5 years) ($P < 0.0001$). The basal mean serum ferritin levels in the 12 months before starting the active treatment at the MRI time were significantly higher in the deferasirox group versus the desferrioxamine group (2491 ± 2072 versus 957 ± 1073 , $P=0.0003$) while they were comparable with the deferiprone group (1665 ± 2028 , $P=0.1$); the basal mean serum ferritin levels were not significantly different between the deferiprone group and the desferrioxamine group ($P = 0.1$). The majority of the study patients were naïve to T2* MRI (85%). The 17 patients with a previous T2* MRI scan were homogeneously distributed in the 3 groups (deferiprone 6/42 patients, desferrioxamine 7/82 patients, deferasirox 4/24 patients; $P = NS$). Out of the 17 patients with a previous T2* MRI, only 2 patients changed the chelation therapy between the two MRI scans. The 2 patients were switched from desferrioxamine

to deferiprone due to an unsatisfactory compliance to the subcutaneous desferrioxamine administration. Anyway, in both patients the study MRI and the previous MRI showed normal global heart T2* values. Baseline clinical findings for the three groups were reported in Table 1.

Global and mid-ventricular septum heart T2* values were significantly higher in the deferiprone-group than the deferasirox and the desferrioxamine groups ($P = 0.0001$) (Fig. 1). Moreover, the number of segments with normal T2* values was significantly higher in the deferiprone and the desferrioxamine groups than in the deferasirox group ($P = 0.0001$).

We did not find significant correlation between the log global heart T2* and the iron chelator dosage (deferiprone $r = -0.13$ $P = 0.45$; desferrioxamine $r = -0.19$ $P = 0.09$; deferasirox $r = -0.098$ $P = 0.762$). The correlation between the log global Heart T2* and the LIC (mg/g dw) was not significant in the deferiprone and deferasirox group ($r = -0.279$ $P = 0.07$, $r = -0.33$ $P = 0.11$, respectively). We found a mild and significant correlation between the log global heart T2* and the LIC (mg/g dw) in the desferrioxamine group ($r = -0.354$ $P = 0.001$).

The deferiprone group showed significantly higher left ventricular ejection fraction than the desferrioxamine and deferasirox groups ($P = 0.010$). Similarly, the right ventricular ejection fraction was higher in the deferiprone group than in the desferrioxamine and deferasirox groups ($P = 0.042$). Although none of the patients suffered from decompensated heart failure (HF) at the time of the scan, 5 patients showed the left ventricular ejection fraction (LVEF) $< 50\%$ (3 patients treated with desferrioxamine and 2 patients treated with deferasirox), 5 patients treated with desferrioxamine showed the right ventricular ejection fraction (RVEF) $< 45\%$, and 1 patient treated with desferrioxamine showed the LVEF $< 50\%$ and the RVEF $< 45\%$. The groups did not show a statistically significant difference in left and right end-diastolic volume indexes and in left ventricular mass index.

Liver Iron Concentrations (mg/g dw) were significantly lower in the desferrioxamine group than in the deferiprone and deferasirox groups ($P = 0.004$).

Mean serum ferritin levels in the last year of the active treatment were significantly higher in the deferasirox-group (2516 ± 2106 ng/ml) vs the desferrioxamine-group (987 ± 915 ng/ml) ($P = 0.001$) while they were comparable with the deferiprone group (1493 ± 1651 ng/ml) ($P = \text{NS}$) (Fig. 4). Comparisons between heart and liver iron and biventricular function parameters in the different groups by MRI are reported in Table 2.

DISCUSSION

The availability of three iron chelators allows physicians to tailor the chelation regimens to the need of different patients. Therefore it is important to establish whether these drugs are differently effective on different organs. Although surrogate markers such as serum ferritin levels and liver iron concentration have been proved to be prognostic indicators in most of the thalassemia patients, they do not always correlate with the cardiac iron burden and function (13, 4, 25). MRI, a technique that provides highly reproducible measurements of myocardial (14-16) and liver iron burden (17, 18), and biventricular function parameters (20), is ideally suited for comparing different chelation treatments in TM patients (3-5). In particular, the method used in this study to quantify the myocardial iron burden assessed not only the $T2^*$ in the mid-ventricular septum, but also the global heart iron and the number of segments with normal $T2^*$ value. This assessment is not usually referred to in studies on thalassaemia patients and it can be advantageous in that the distribution of iron in the heart is heterogeneous (15, 27).

Our large multicentre observational study showed that TM patients treated with deferiprone alone had significantly less global and segmental myocardial iron burden and significantly better global systolic ventricular function than patients treated with desferrioxamine and deferasirox alone for a minimum of 12 months at comparable levels of compliance (Fig. 1-2). Moreover, none of the patients treated with deferiprone showed $\text{LVEF} < 50\%$ and/or $\text{RVEF} < 45\%$ that can be considered indicative of heart failure in thalassemia major patients (28). Conversely, the desferrioxamine group showed less liver iron burden than the patients treated with the other two chelators (Fig. 3).

The chelation starting age and the exposure to intensive chelation therapy were not significantly different among groups. All three groups showed high and comparable levels of compliance. In our outpatients population compliance data were collected by the investigators of each thalassemia centre and seem to be concordant with the levels of liver and cardiac iron burden. This datum could be justified by the organization of the national health system, by the free availability to MRI exams and by the support of the voluntary associations and of the family. As expected, in our study population, desferrioxamine, which has been on the market for the past thirty years, had been started significantly earlier than the deferiprone and the deferasirox treatments.

Deferiprone and deferasirox groups showed comparable basal mean serum ferritin levels. Thus, we cannot attribute the most efficacy of deferiprone in removing/preventing cardiac iron to a lower baseline iron burden.

A previous knowledge of cardiac iron burden seems to have not introduced any bias in our study population. In fact, a high percentage of the patients (85%) were naïve to T2* MRI and patients with a previous T2* MRI were homogeneously distributed in the 3 groups. Moreover, of the patients with a previous T2* MRI, only 2 patients had changed the chelation therapy between the two MRI scans and these 2 patients had normal global heart T2* values in both scans and the change in the chelation therapy was due to compliance reasons.

Previous retrospective (3, 4) and prospective randomized clinical trials (5) have shown deferiprone to be more effective than subcutaneous desferrioxamine in preventing and removing myocardial iron burden and improving survival (2, 6-9).

In one preliminary prospective study recently published (10), deferasirox when given at a mean dosage of 32.6mg/kg/day for one year, in TM patients with cardiac iron and normal/borderline left ventricular ejection fraction led to negative cardiac and liver iron balance and maintained ejection fraction. One observational prospective, open-label, single-arm study (11) suggested that deferasirox monotherapy, administered at the dose of 30-40 mg/kg/day for 18 months maintained unchanged the ejection fraction in patients with normal/borderline left ventricular ejection fraction

and was effective in patients with mild-to-moderate iron stores in removing cardiac iron but failed in patients with severe hepatic iron burdens. Another single-arm observational study showed significant improvement in cardiac T2* in heavily iron loaded TM patients receiving iron deferasirox over an 18-month period (12). All these studies were limited by the short period of treatment evaluation.

On the contrary, a recently published not prospectively and not randomised observational study from Greece showed no statistically significant improvement in cardiac iron load in thalassemia major patients on deferasirox at any level of cardiac iron loading (13).

In the three above mentioned prospective studies (10-12), as opposed to the Greek study (13) and to the ours, deferasirox was given at higher doses (30 mg/kg/day with the possibility to increase the dose to over 40 mg), possibly explaining the different results obtained. Moreover, out of the 24 patients in the deferasirox group, 13 patients had participated in clinical trial in the 12 months before the MRI. In this subgroup the mean dosage of the deferasirox in the last 12 months before the scan was 30 ± 7 mg/kg/day (range 20- 40 mg/kg/day) and we cannot exclude a previous under dosing. Anyway, in our study population we did not find significant correlation between the global heart T2* and the drug dosage of the three iron chelators.

With respect to the liver, in contrast to the lower myocardial iron overload in the deferiprone group, the desferrioxamine group showed significantly higher liver iron T2* values than the other two groups and significantly lower mean serum ferritin levels in the last year of treatment than the deferasirox group. The significantly lower mean ferritin levels and LIC in the desferrioxamine group versus the deferasirox group could be influenced by the significantly lower basal serum ferritin levels in the desferrioxamine group versus the deferasirox group. The ability of desferrioxamine to significantly reduce body iron burden has been repeatedly demonstrated (29). However, in all the series reported, 65% of the patients treated with desferrioxamine alone were found to have a T2* in the mid ventricular septum less than 20 ms and therefore less than an optimal target (30). These findings confirm a possible important difference in drug action:

deferiprone seems to be a better agent for removing/preventing myocardial siderosis, but less effective in removing hepatocellular iron, while the opposite appears to be true for desferrioxamine (4, 5, 30). The data available in literature for the deferasirox seem to confirm a good action on the liver, but the data regarding the heart are so far preliminary and contradictory.

The limits of our study were that it was a retrospective and a non-randomized study. Several bias could be present. First, the duration of the treatment was significantly shorter for deferasirox versus desferrioxamine and this drug could be effective on the heart only after a longer time of treatment considering that cardiac iron removal is a slow process with a clearance rate around 1.5% per month (11). Second, even though the low percentage of patients who had previous combination therapy was not significantly different among the three groups, the higher percentage in the deferiprone group could have influenced the results. Third, the prescription of a particular regime was made based on clinical grounds and on evidence-based medicine. However, the prescription based on evidence-based medicine would have avoided the preferential prescription of deferasirox in the patients with greater iron load and at high risk for cardiac complications. In fact, at the time of the patients' enrolment the deferiprone had proved to be more effective than subcutaneous desferrioxamine for removing heart iron and in improving survival (5-6). Thus, the deferasirox was prescribed for contradictions or non optimal compliance to the others chelators, or in patients preferring a more friendly oral and once daily chelator. Moreover, 13 patients started deferasirox because they were enrolled in clinical trial and the patients with a poor response or noncompliance with previous prescribed therapy were excluded (31).

In conclusion, in patients treated for a minimum of 12 months at comparable levels of compliance, oral deferiprone showed less myocardial iron burden and better left global systolic ventricular function compared to the patients treated with oral deferasirox or subcutaneous desferrioxamine suggesting more efficacy in removing or preventing cardiac iron, with a concordant positive effect on the heart function. Conversely desferrioxamine appeared to be more effective in removing or preventing iron deposition in the liver. However, well designed, prospective and randomized

comparative clinical trials are clearly necessary, as difficult as they may be, in order to prescribe the most appropriate chelator (or a combination thereof) for the individual thalassemia major patient.

Authorship and Disclosures

AP: original idea, designed the study, data acquisition and analysis, wrote the paper; AM and GR statistical analysis and reviewed the manuscript; MC, PC, LP, CM, MCP, AP, MAR, MGB, AF, VC, AQ, LP, MM, MM: data acquisition and reviewed the paper; VP: data analysis and reviewed the paper; ML designed the study, data acquisition and reviewed the manuscript; AM: designed the study, data acquisition, data analysis and reviewed the manuscript.

AP received speaker's honoraria from Chiesi and Apotex, ML received speaker's honoraria from Apotex.

REFERENCES

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematologica*. 2004;89(10):1187-93.
2. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. *Blood Cells Mol Dis*. 2009;42(3):247-51.
3. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. *Lancet*. 2002;360(9332):516-20.
4. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. *Eur J Haematol*. 2006;76(3):183-92.

5. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. *Blood*. 2006;107(9):3738-44.
6. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. *Blood*. 2006;107(9):3733-7.
7. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. *Haematologica*. 2003;88(5):489-96.
8. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, et al. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. *Haematologica*. 2006 Oct;91(10):1420-1.
9. Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E, et al. Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004. *Haematologica*. 2006;91(9):1187-92.
10. Pennell D, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of Deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. *Blood*. 2010 Mar 25;115(12):2364-71.
11. Wood JC, Kang B, Thompson AA, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. *Blood*. 2010; 0: blood-2009-11-250308v1-blood-2009-11-250308.
12. Pathare A, Taher A, Daar S. Deferasirox (Exjade(R)) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. *Ann Hematol*. *Ann Hematol*. 2010;89(4):405-9.

13. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. *J Cardiovasc Magn Reson*. 2009;11(1):20.
14. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001;22(23):2171-9.
15. Pepe A, Positano V, Santarelli F, Sorrentino F, Cracolici E, De Marchi D, et al. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. *J Magn Reson Imaging*. 2006;23(5):662-8.
16. Westwood MA, Firmin DN, Gildo M, Renzo G, Stathis G, Markissia K, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. *Int J Cardiovasc Imaging*. 2005;21(5):531-8.
17. Positano V, Salani B, Pepe A, Santarelli MF, De Marchi D, Ramazzotti A, et al. Improved T2* assessment in liver iron overload by magnetic resonance imaging. *Magn Reson Imaging*. 2009;27(2):188-97.
18. Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassaemia major. *Blood*. 2008;112(7):2973-8.
19. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. *J Cardiovasc Magn Reson*. 2008;10(1):42.
20. Sironi M, Lombardi M, Pepe A, De Marchi D. Study of heart function In: eds. S-VI, editor. *MRI of Heart and Vessels* Lombardi M, Bartolozzi C; 2005.
21. Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, et al. Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial iron. *J Magn Reson Imaging*. 2009;30(1):62-8.

22. Meloni A, Ramazzotti A, Positano V, Salvatori C, Mangione M, Marcheschi P, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. *Int J Med Inform.* 2009;78:503-12.
23. Positano V, Pepe A, Santarelli MF, Scattini B, De Marchi D, Ramazzotti A, et al. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. *NMR Biomed.* 2007;20:578-90.
24. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. *Circulation.* 2002;105(4):539-42.
25. Aessopos A, Fragodimitri C, Karabatsos F, Hatziliami A, Yousef J, Giakoumis A, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. *Haematologica.* 2007;92(1):131-2.
26. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. *Blood.* 2005;106(4):1460-5.
27. Positano V, Pepe A, Santarelli MF, Ramazzotti A, Meloni A, De Marchi D, et al. Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. *NMR Biomed.* 2009;22(7):707-15.
28. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, et al. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. *J Magn Reson Imaging.* 2007 Jun;25(6):1147-51.
29. Roberts DJ, Rees D, Howard J, Hyde C, Alderson P, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. *Cochrane Database Syst Rev.* 2005(4):CD004450.

30. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. *J Cardiovasc Magn Reson.* 2006;8(3):543-7.
31. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with α -thalassemia. *Blood.* 2006;107(9):3455-62.

Table 1. Clinically relevant findings in the three groups of chelation treatment.

	Deferiprone group (n = 42)	Desferrioxamine group (n = 89)	Deferasirox group (n = 24)	<i>P</i>
Age (years)	31±9	33±8	26±7 (*)	0.001
M/F	20/22	42/47	11/13	NS
Pre-transfusion Hb (g/dl)	9.5±0.7	9.6±0.6	9.7±0.5	NS
Chelation starting age (years)	8±10	5±3	5±5	NS
Active treatment duration (years)	4±4	24±10	2±1	0.0001
Excellent /good compliance (%)	93	93	92	NS
Previous 24 h DFO portacaths (%)	2	1	0	NS
Previous Combination Therapy (%)	12	6	8	NS
Previous Intensive Chelation Therapy (%)	14	7	8	NS

NS: not significant. DFO: desferrioxamine.

Table 2. Comparison of MRI data (heart and liver iron, and biventricular function parameters) among the three different groups of chelation treatment.

	Deferiprone group (n=42)	Desferrioxamine group (n=89)	Deferasirox group (n=24)	<i>P</i>
Global Heart T2* (ms)	34±11	27±11	21±12	0.0001
Mid-Ventricular septum T2* (ms)	36±13	29±14	20±12	0.0001
N. of segments with normal T2*	11±4	9±5	5±5	0.0001
Liver T2* (ms)	6±6	10±9	5±5	0.004
Liver Iron Concentration (mg/g dw)	11±11	7±8	12±10	0.004
Left ventricular EF (%)	64±6	61±7	59±7	0.010
Left end-diastolic volume index	89±16	90±19	89±21	NS
Left end-systolic volume index	32±9	35±12	37±12	NS
Left Ventricular Mass Index (g/m ²)	63±7	60±12	60±16	NS
Right ventricular EF (%)	63±7	59±8	60±5	0.042
Right end-diastolic volume index	87±16	88±20	88±21	NS
Right end-systolic volume index	32±8	37±15	35±11	NS

EF: ejection fraction, NS: not significant.

Figure 1. Global heart T2* and the T2* in the mid-ventricular septum in the groups treated with deferiprone, desferrioxamine and deferasirox. There were significant differences among groups ($P=0.0001$). Post hoc analysis showed significantly higher global heart T2* and T2* in the mid-ventricular septum in the group treated with deferiprone vs the group treated with desferrioxamine and deferasirox. Each box shows the median, quartiles, and extreme values within the category.




Figure 2. Left ventricular ejection fraction in the groups treated with deferiprone, desferrioxamine and deferasirox. There were significant differences among groups ($P = 0.001$). Post hoc analysis showed a significantly higher left ventricular ejection fraction in the group treated with deferiprone vs the group treated with deferasirox. Each box shows the median, quartiles, and extreme values within the category.




Figure 3. Estimated MRI LIC (mg/g dw) in the groups treated with deferiprone, desferrioxamine and deferasirox. There were significant differences among groups ($P=0.004$). Post hoc analysis showed a significantly lower LIC in the group treated with desferrioxamine vs the group treated with deferiprone and the group treated with deferasirox. Each box shows the median, quartiles, and extreme values within the category.




Figure 4. Mean serum ferritin in the groups treated with deferiprone, desferrioxamine and deferasirox. There were significant differences among groups ($P=0.002$). Post hoc analysis showed a significantly higher mean ferritin value in the group treated with deferasirox vs the group treated with desferrioxamine. Each box shows the median, quartiles, and extreme values within the category.

